{
"id":"mk19_bb_hm_s24",
"subspecialtyId":"hm",
"title":"Transfusion Medicine",
"jsonContent":{
"type":"section",
"id":"mk19_bb_hm_s24",
"title":{
"__html":"Transfusion Medicine"
},
"titleNode":{
"type":"section-title",
"hlId":"e1fce3",
"children":[
"Transfusion Medicine"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_hm_s24_1",
"title":{
"__html":"Transfusions"
},
"titleNode":{
"type":"section-title",
"hlId":"5a1a82",
"children":[
"Transfusions"
]
},
"children":[
{
"type":"p",
"hlId":"c2cc81",
"children":[
"Erythrocytes, platelets, plasma, cryoprecipitates, and (rarely) whole blood may be used for transfusion."
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"dfe228",
"children":[
"Each unit of packed red blood cells results in a hemoglobin level increase of 1 g/dL."
]
},
" ",
{
"type":"list-item",
"hlId":"754b1b",
"children":[
"Each unit of platelets transfused results in a 20,000 to 30,000/μL increase in platelets."
]
},
" "
]
},
{
"type":"p",
"hlId":"b23c23",
"children":[
"In emergencies:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"08c23e",
"children":[
"Group O erythrocytes can be transfused to anyone."
]
},
" ",
{
"type":"list-item",
"hlId":"f714bb",
"children":[
"Group AB plasma and platelets can be transfused to anyone."
]
},
" ",
{
"type":"list-item",
"hlId":"74ec2c",
"children":[
"Patients who are Rh(D) positive can safely receive either D-positive or D-negative blood, but patients who are ",
{
"type":"alert",
"children":[
"Rh(D) negative must receive D-negative blood and platelets."
]
}
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s24_2",
"title":{
"__html":"Replacement of Coagulation Factors"
},
"titleNode":{
"type":"section-title",
"hlId":"884635",
"children":[
"Replacement of Coagulation Factors"
]
},
"children":[
{
"type":"p",
"hlId":"6bec8b",
"children":[
{
"type":"abbreviation",
"title":"fresh frozen plasma",
"children":[
"FFP"
]
},
" is used to replace coagulation factors. FFP is not needed for treating mild coagulopathies characterized by an ",
{
"type":"abbreviation",
"title":"international normalized ratio",
"children":[
"INR"
]
},
" <1.9."
]
},
{
"type":"p",
"hlId":"de1f1b",
"children":[
"Cryoprecipitates (factor VIII, fibrinogen, ",
{
"type":"abbreviation",
"title":"von Willebrand factor",
"children":[
"vWF"
]
},
") are an adjunct to FFP replacement therapy and are used mainly for their fibrinogen content in patients with ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"disseminated intravascular coagulation",
"children":[
"DIC"
]
},
"."
]
}
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_hm_s24_inline_t1"
],
"forceOpen":true
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s24_3",
"title":{
"__html":"Transfusion Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"11e094",
"children":[
"Transfusion Complications"
]
},
"children":[
{
"type":"p",
"hlId":"32c14c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"An acute hemolytic transfusion reaction"
]
},
" results from ABO incompatibility. Characteristic findings are:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"e38427",
"children":[
"fever and chills"
]
},
" ",
{
"type":"list-item",
"hlId":"6053e5",
"children":[
"flank and abdominal pain"
]
},
" ",
{
"type":"list-item",
"hlId":"171de3",
"children":[
"dyspnea"
]
},
" ",
{
"type":"list-item",
"hlId":"9c170d",
"children":[
"hypotension and tachycardia"
]
},
" ",
{
"type":"list-item",
"hlId":"94ca35",
"children":[
"red plasma and urine"
]
},
" ",
{
"type":"list-item",
"hlId":"59a1ad",
"children":[
"free hemoglobin in the plasma"
]
},
" ",
{
"type":"list-item",
"hlId":"ac26d9",
"children":[
"positive ",
{
"type":"abbreviation",
"title":"direct antiglobulin test",
"children":[
"DAT"
]
},
" (Coombs test)"
]
},
" "
]
},
{
"type":"p",
"hlId":"808ffe",
"children":[
"Treatment of acute hemolytic transfusion reaction consists of transfusion discontinuation, IV hydration, and appropriate cardiovascular support."
]
},
{
"type":"p",
"hlId":"02b107",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"A delayed hemolytic transfusion reaction"
]
},
" results from delayed emergence of an alloantibody that causes rapid extravascular clearance of transfused erythrocytes 2 to 10 days after transfusion. Characteristic findings are low-grade fever and an unexplained drop in hemoglobin concentration, elevated serum bilirubin and ",
{
"type":"abbreviation",
"title":"lactate dehydrogenase",
"children":[
"LDH"
]
},
" levels, increased reticulocyte count, decreased haptoglobin concentration, and the presence of a new alloantibody."
]
},
{
"type":"p",
"hlId":"03aed6",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"A febrile nonhemolytic transfusion reaction"
]
},
" can occur during or after a transfusion; it is caused by donor leukocyte cytokines or recipient alloantibodies directed against donor leukocytes. The transfusion should be stopped, hemolytic transfusion reaction ruled out, and antipyretic agents given."
]
},
{
"type":"p",
"hlId":"bf7656",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Transfusion-related acute lung injury (TRALI)"
]
},
" is a rare, severe reaction caused by donor antileukocyte antibodies reacting with recipient leukocytes and causing leukocyte aggregation in the pulmonary capillary bed, usually during or within 6 hours of transfusing erythrocytes, platelets, or FFP. ",
{
"type":"alert",
"children":[
"Characteristic findings are hypoxemia and noncardiogenic pulmonary edema."
]
},
" The transfusion should be stopped and respiratory support provided."
]
},
{
"type":"p",
"hlId":"b800ce",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Transfusion-associated circulatory overload (TACO)"
]
},
" is the most common serious complication of blood transfusion and is more likely in patients with underlying heart or kidney disease but should be considered in any patient with new respiratory symptoms during or within 6 hours of transfusion. Management is the same as cardiogenic pulmonary edema."
]
},
{
"type":"p",
"hlId":"3e9053",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"An allergic transfusion reaction"
]
},
" occurs when donor plasma constituents react with a recipient's IgE on mast cells. Characteristic findings are rash, hives, wheezing, and mucosal edema. Treatment includes antihistamines and glucocorticoids. ",
{
"type":"alert",
"children":[
"Patients with IgA deficiency are at high risk because of the presence of anti-IgA antibodies."
]
}
]
},
{
"type":"p",
"hlId":"b79c04",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Transfusion-associated "
]
},
{
"type":"abbreviation",
"title":"graft-versus-host disease",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"GVHD"
]
}
]
},
" is a rare but fatal complication in which donor lymphocytes engraft in an immunocompromised or ",
{
"type":"abbreviation",
"title":"human leukocyte antigens",
"children":[
"HLA"
]
},
"-similar recipient and cause reactions that affect the bone marrow, liver, skin, and ",
{
"type":"abbreviation",
"title":"gastrointestinal",
"children":[
"GI"
]
},
" tract. Patients at risk are immunosuppressed."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_bb_hm_s24_inline_t2"
],
"forceOpen":true
}
]
}
]
},
"tablesContent":{
"mk19_bb_hm_s24_inline_t1":{
"id":"mk19_bb_hm_s24_inline_t1",
"number":1,
"bookId":"hm",
"title":{
"__html":"Study Table: Threshold Values for Prophylactic Transfusion"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"30a540",
"children":[
"Study Table: Threshold Values for Prophylactic Transfusion"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e2941",
"class":"col hd l",
"children":[
"Condition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a50c1",
"class":"col hd l",
"children":[
"Threshold to Transfuse"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e1e9a0",
"class":"cell txt l",
"children":[
"Platelet transfusion; no other risk factors for bleeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e05f22",
"class":"cell txt l",
"children":[
"10,000-20,000/μL"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42d84e",
"class":"cell txt l",
"children":[
"Platelet transfusion for neurosurgery or intracranial bleeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5ec8d8",
"class":"cell txt l",
"children":[
"100,000/μL"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"211a7a",
"class":"cell txt l",
"children":[
"Platelet transfusion; bleeding or planned surgery"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b82b1f",
"class":"cell txt l",
"children":[
"50,000/μL"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d45d32",
"class":"cell txt l",
"children":[
"Hemoglobin for most medical and surgical patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ec2cc",
"class":"cell txt l",
"children":[
"7 g/dL"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_bb_hm_s24_inline_t2":{
"id":"mk19_bb_hm_s24_inline_t2",
"number":2,
"bookId":"hm",
"title":{
"__html":"Study Table: Cellular Transfusion Product Modifications"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3ae018",
"children":[
"Study Table: Cellular Transfusion Product Modifications"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8af1f1",
"class":"col hd l",
"children":[
"Modification"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2dce8f",
"class":"cell txt l",
"children":[
"Leukoreduction"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d81dd",
"class":"cell txt l",
"children":[
"Reduces the number of leukocytes present in the transfused product. Reduces platelet transfusion refractoriness, febrile nonhemolytic transfusion reactions, and transmission of ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"cytomegalovirus",
"children":[
"CMV"
]
},
"."
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d8a83f",
"class":"cell txt l",
"children":[
"Irradiation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"24d13e",
"class":"cell txt l",
"children":[
"Used to prevent transfusion-associated GVHD, which is mediated by donor lymphocytes."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"418fa4",
"class":"cell txt l",
"children":[
"Washing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd38f9",
"class":"cell txt l",
"children":[
"Removes the proteins residing in the small amount of plasma in erythrocyte and platelet transfusions and is used in patients with a history of allergic reactions, IgA deficiency, or complement-dependent autoimmune hemolytic anemia."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}